The impact of this launch can be assessed through prescription trends, adoption rates in clinical practice, and its role within existing diabetes management frameworks
Patients with normal or near-normal BMI often qualify for GLP-1 therapy based on type 2 diabetes diagnosis, cardiovascular risk factors, or metabolic markers indicating therapeutic benefit
The sloppy joe filling can even be frozen for use at a later time
Many patients begin noticing progress within the first few weeks when they follow their treatment plan consistently
In the Phase 2 trial, participants on retatrutide showed significant reductions in hepatic fat content, with some achieving near-complete resolution of metabolic associated steatotic liver disease
By improving insulin sensitivity, reducing inflammation, and supporting energy metabolism, it aligns with broader goals in wellness and healthy agingareas of growing interest for both patients and practitioners